Physician profile
Raul L Vilca
NPI 1447419726
$1,929.83
in general payments reported to CMS, 2019-2025
19 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $232 · 2021: $405 · 2022: $423 · 2023: $238 · 2024: $86.19 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $389.97 | 2019-2022 | |
| Amgen INC. | $292.36 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $228.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.93 | 2020-2025 | Jardiance |
| Boston Scientific Corporation | $148.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $114.36 | 2021-2025 | Verquvo |
| Pfizer INC. | $70.26 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $62.88 | 2022-2023 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $62.36 | 2021-2025 | Camzyos |
| Abbott Laboratories | $56.62 | 2020-2021 | |
| Heartflow, INC. | $56.55 | 2023-2025 | Ffrct |
| Atricure, INC. | $50.17 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.51 | 2019 | |
| Gilead Sciences, INC. | $32.99 | 2019 | |
| Philips North America LLC | $29.17 | 2025 | Mcot |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $24.60 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.41 | 2024 | Farxiga |
| Irhythm Technologies, INC. | $17.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Vilca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.